Slide 1: Stock exchange cover letter for investor presentation
6th November, 2020 [Grab your reader’s attention with a great quote from the document or use this space to emphasize a key point. To place (1) BSE Limited (2) National Stock Exchange of India Limited this text box anywhere on the page, just drag it.] Listing Department, Listing Department [Cite your
Slide 2: Investor Presentation Q2FY21
Investor Presentation Q2FY21 06-11-2020
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward- looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors tha
Slide 4: Cipla's efforts in combatting Covid-19
Cipla’s efforts in combatting Covid-19 Delivering on our promise of ‘Caring for life’ Patients Physicians Employees ❖ 1.5 lakhs+ severe Covid-19 patients ❖ Teleconsultation support to 20,000+ ❖ Continued work from home with serviced with supply of Actemra ®, doctors to ensure safe and several enabli
Slide 5: Strong demand, resilient operations and cost control drive Q2 performance
Strong demand, resilient operations and cost control drive Q2 performance Overall Revenues 1 India delivers growth across all lines of business 15% 16% One India India Rx India Gx CHL (YoY Growth) (QoQ Growth) 17% 30% 5th consecutive 2x growth Strong demand YoY led by organic Robust performance acro
Slide 6: Continued progress across our key strategic priorities
Continued progress across our key strategic priorities South Africa & Emerging One-India US Generics markets • Continue to drive synergies • 3rd largest within the SA private • Continue to build the US pipeline across the three businesses market with 7.0% market share1; with differentiated products
Slide 7: Continued focus on maintaining balance sheet health with strong cash flow generation
Continued focus on maintaining balance sheet health with strong cash flow generation Net Debt Net Debt / Equity Cash Balances1 807 0.05 3,623 Net cash Net cash positive position positive position 2,009 (453) (0.03) Mar'20 Sept'20 Mar'20 Sept'20 Mar'20 Sept'20 ▪ Strong governance set-up for cash and
Slide 8: Financial Performance – Q2FY21
Financial Performance – Q2FY21 Revenues INR 5,038 Cr 15% YoY EBITDA INR 1,177 Cr │ 23.4% 29% YoY Q2 FY21 (Consolidated) Revenue1 Break-up Actuals Others, vs Q2 FY 20 Global API, 4% (Rs Cr) 1% Total Revenue from Europe, 5% 5,038 15% Operations Emerging Mkts, 9% EBITDA 1,177 29% India, 41% EBITDA % of
Slide 9: India (Rx + Gx + CHL): Consistent execution driving growth across businesses in India
India (Rx + Gx+ CHL1): Consistent execution driving growth across businesses in India Q2 Y-o-Y Rs Cr India Rx 14% 2,090 13%13% 14% 12% 17% 10% 10% 9% 1,789 4% 5th consecutive quarter of market -4% beating growth Q2FY20 Q3FY20 Q4FY20 Q1FY21 Q2FY21 IPM YoY Growth Cipla India Rx (Reported) YoY Growth Q
Slide 10: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA1: South Africa, Sub-Saharan Africa and Cipla Global Access Q2 Y-o-Y $ Mn South Africa Market 14% Q2 YoY 48 28 ZAR Terms 21 24 South Africa Private South Africa Tender South Africa Private 9% Q2 YoY 28% Q2 YoY South Africa 56 53 ZAR Terms ZAR Terms Tender Others (SSA & CGA) Q2 FY20 Q2 FY21 Key B
Slide 11: North America: Growth driven by continued momentum in new launches
North America: Growth driven by continued momentum in new launches Key Business Highlights Q2 Y-o-Y • Continued traction in new launches namely $ Mn Albuterol, Esomeprazole oral suspension and DHE Nasal Spray supporting the base business; Launched dimethyl fumarate DR capsules 141 135 4% Healthy YoY
Slide 12: ANDA Portfolio & Pipeline (As on 30th Sept 2020)
ANDA1 Portfolio & Pipeline (As on 30th Sept 2020) Total 165 19 66 250 ANDAs ANDA Portfolio 22 56 9 4 21 78 4 1 3 37 10 5 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs Cipla Ltd PEFPAR 2 Invagen Partnered ANDAs 1 Does not include Vet product ANDAs 2 PEPFAR approved ANDAs can be comme
Slide 13: Emerging Markets, Europe and API
Emerging Markets, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn 33 64 64 24% 25 27 15% 22 Q2 FY20 Q2 FY21 Q2 FY20 Q2 FY21 Q2 FY20 Q2 FY21 ▪ Maintained scale with continued demand across all regions ▪ Strong performance in key DTM1 ▪ Strong sales momentum and markets orderbook ▪ Remdesivi
Slide 14: Priorities for the coming quarters: Sustaining growth through the pandemic
Priorities for the coming quarters: Sustaining growth through the pandemic Digital • Adopting digital transformation for patient and channel connect to expand access and leverage demand patterns adoption and 1 resilient • Proactively de-risking the business by diversifying sources for critical APIs,
Slide 15: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q2FY21 14